Effects of angiotensin II type 1 receptor blocker on bones in mice with type 1 diabetes induced by streptozotocin

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 3, 2014, Pages 218-227

  Zhang, Yan ^a,b   Diao, Teng Yue ^a   Gu, Sa Sa ^a   Wu, Shu Yan ^a   Gebru, Yoseph A ^a   Chen, Xi ^a   Wang, Jing Yu ^c   Ran, Shu ^a   Wong, Man Sau ^b  

^a UNIVERSITY OF SHANGHAI FOR SCIENCE AND TECHNOLOGY   (China)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Bone; losartan; osteoporosis; renin angiotensin system; streptozotocin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSINOGEN; LOSARTAN; MESSENGER RNA; RENIN; GLUCOSE BLOOD LEVEL; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE RADIOGRAPHY; CONTROLLED STUDY; DIABETIC OSTEOPOROSIS; DRUG EFFECT; GENE EXPRESSION; IMMUNOBLOTTING; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METAPHYSIS; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; PHENOTYPE; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; UPREGULATION; ANIMAL; BLOOD; BODY WEIGHT; BONE; DBA MOUSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMUR; GENETICS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOLOGY; RADIOGRAPHY; TIBIA; URINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; BONE AND BONES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FEMUR; MALE; MICE, INBRED DBA; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; STREPTOZOCIN; TIBIA; X-RAY MICROTOMOGRAPHY;

EID: 84881521064     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320312471229     Document Type: Article

References (32)

1. Namazi S, Ardeshir-Rouhani-Fard S, Abedtash H. The effect of renin angiotensin system on tamoxifen resistance. Med Hypotheses. 2011 ; 77: 152-155
2. Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia. 2004 ; 47: 240-248
3. Zhang Z, Zhang Y, Ning G, et al. Combination therapy with AT1 receptor blocker and vitamin D analog markedly ameliorates diabetic nephropathy. Proc Natl Acad Sci USA. 2008 ; 105: 15896-15901
4. Zhang Y, Deb DK, Kong J, et al. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: Strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009 ; 297: F791 - F801
5. Koïtka A, Cao Z, Koh P, et al. Angiotensin II subtype 2 receptor blockade and deficiency attenuate the development of atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes. Diabetologia. 2010 ; 53: 584-592
6. Inaba S, Iwai M, Furuno M, et al. Role of angiotensin-converting enzyme 2 in cardiac hypertrophy induced by nitric oxide synthase inhibition. J Hypertens. 2011 ; 29: 2236-2245
7. Asaba Y, Ito M, Fumoto T, et al. Activation of renin-angiotensin system induces osteoporosis independently of hypertension. J Bone Miner Res. 2009 ; 24: 241-250
8. Izu Y, Mizoguchi F, Kawamata A, et al. Angiotensin II type 2 receptor blockade increases bone mass. J Biol Chem. 2009 ; 284: 4857-4864
9. Shimizu H, Nakagami H, Osako MK, et al. Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J. 2008 ; 22: 2465-2475
10. Hiruma Y, Inoue A, Hirose S, et al. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae. Biochem Biophys Res Commun. 1997 ; 230: 176-178
11. Gu SS, Zhang Y, Li XL, et al. Involvement of the skeletal renin-angiotensin system in age-related osteoporosis of ageing mice. Biosci Biotechnol Biochem. 2012 ; 76: 1367-1371
12. Garcia P, Schwenzer S, Slotta JE, et al. Inhibition of angiotensin-converting enzyme stimulates fracture healing and periosteal callus formation - role of a local renin-angiotensin system. Br J Pharmacol. 2010 ; 159: 1672-1680
13. Hofbauer LC, Brueck CC, Singh SK, et al. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res. 2007 ; 22: 1317-1328
14. Vijan SG. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients. J Indian Med Assoc. 2009 ; 107: 178-182
15. Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol. 2010 ; 105: 30A - 35A
16. Wright AD, Dodson PM. Diabetic retinopathy and blockade of the renin-angiotensin system: New data from the DIRECT study programme. Eye (Lond). 2007 ; 24: 1-6
17. Danser AH. The increase in renin during renin inhibition: Does it result in harmful effects by the (pro)renin receptor?. Hypertens Res. 2010 ; 33: 4-10
18. Deb DK, Sun T, Wong KE, et al. Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney Int. 2010 ; 77: 1000-1009
19. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag. 2011 ; 7: 749-759
20. Yung LM, Wong WT, Tian XY, et al. Inhibition of renin-angiotensin system reverses endothelial dysfunction and oxidative stress in estrogen deficient rats. PLoS One. 2011 ; 6: e17437
21. Dalla Vestra M, Simioni N, Masiero A. Renal effects of dual renin-angiotensin-aldosterone system blockade in patients with diabetic nephropathy. Int Urol Nephrol. 2009 ; 41: 119-126
22. Li YC. Inhibition of renin: An updated review of the development of renin inhibitors. Curr Opin Investig Drugs. 2009 ; 8: 750-757
23. Zhang Y, Papasian CJ, Deng H. Alteration of vitamin D metabolic enzymes expression and calcium transporters abundance in kidney involved in type 1 diabetes-induced bone loss. Osteoporos Int. 2011 ; 22: 1781-1788
24. Koiwa F, Komukai D, Hirose M, et al. Influence of renin-angiotensin system on serum parathyroid hormone levels in uremic patients. Clin Exp Nephrol. 2012 ; 16: 130-135
25. An J, Nakajima T, Kuba K, et al. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages. Hypertens Res. 2010 ; 33: 831-835
26. Kawai M, Rosen CJ. PPAR: A circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol. 2010 ; 6: 629-636
27. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002 ; 111: 305-317
28. Kaneko K, Ito M, Fumoto T, et al. Physiological function of the angiotensin AT1a receptor in bone remodeling. J Bone Miner Res. 2011 ; 26: 2959-2966
29. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006 ; 20: 953-970
30. Lynn H, Kwok T, Wong SY, et al. Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone. 2006 ; 38: 584-588
31. García-Tesal A, Monzó A, Rabanaque G, et al. Evolution of the bone mass of hypertense menopausal women in treatment with fosinopril. Med Clin (Barc). 2006 ; 127: 692-694
32. Kwok T, Leung J, Zhang YF, et al. Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?. Osteoporos Int. 2012 ; 23: 2159-2167